(NewsNation) — Dr. Oz once asked the question on his titular talk show, “Could a diabetes drug cure obesity?” He was referring to semaglutide, better known as Ozempic and Wegovy, following a surge in demand for the medication.
A new medical study published this month suggests yes — with some key factors to keep in mind.
Ozempic’s long-term impact
Long-term weight loss for patients with obesity proved mostly successful after taking prescription-only injectable semaglutide, the Cleveland Clinic found.
Researchers at the nonprofit academic and research medical center identified key factors that impact the effectiveness of the widely popular medication.
Some patients were prescribed to treat obesity (more than 100 million American adults have obesity, according to the Centers for Disease Control), and others to treat Type 2 diabetes, its original approved use. Dosage and frequency especially affected weight reduction.
“Clinical trials have shown that anti-obesity medications are effective,” the study says, although calling for a need for more data in “real-world settings.” About 3,400 patients, more than half female, with obesity participated in the study. The study determined females had a better percentage of successful weight loss after one year than males did.
Results from the study suggest patients lost more weight with higher dosages of semaglutide than those who took less. Patients who took the medication consistently for more than 90 days had more success than those who took it over less time.
“Ozempic works by targeting GLP-1 receptors in the brain, which regulate appetite and blood sugar levels, for an effective means of weight control,” said Marlee Bruno, a certified physician’s assistant and founder of Mind Body & Soul Medical in Pensacola, Florida.
“It is important to note that Ozempic is not a magic fix. It must be utilized as a tool, with users incorporating essential lifestyle changes, like increasing protein intake, staying well-hydrated, exercising regularly and avoiding processed, unhealthy foods,” Bruno added.
Overwhelming Ozempic demand
First approved by the Food and Drug Administration (FDA) in 2017 to treat Type 2 diabetes, Ozempic became a household name over time and a social media topic of discussion for its weight loss capabilities.
The rise in popularity can be attributed, in large part, to the viral #OzempicChallenge on TikTok and endorsements from popular influencers. The FDA even declared a shortage following the increased demand.
“Studies have shown that achieving sustained weight loss of 10% or more provides clinically significant health benefits,” the study notes.
Some thought the drug was just a fleeting trend, but it is beneficial to those with an actual need for it.
‘Far from a fad’
“I can confidently say that Ozempic is far from a fad. It’s a scientifically backed treatment that addresses the root causes of obesity, not just the symptoms,” Bruno told NewsNation. “When used responsibly alongside imperative lifestyle changes, Ozempic is an absolute game-changer in weight management and can lead to lasting, healthy outcomes.”
Ozempic’s sister brand Wegovy, which has a higher dosage of semaglutide, is in limited supply. The FDA cites “demand increase for the drug” as the shortage reason. The FDA’s shortage announcement first came in August 2022 and remains in the “currently in shortage” status.
Like with any drug, there are risks that patients should discuss with their doctor. The FDA warned in July of the possibility of overdosing on these products. And another medical study found that bones can become less dense with rapid weight loss, especially in people older than 65 and predisposed to osteoporosis.
“It’s crucial to use the medication as directed under the guidance of a medical expert who can adjust the dosage as needed and monitor progress,” Bruno said.